The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Long-acting Injectable Antipsychotics (LAIs) Market Research Report 2025
Synopsis
Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.
The global Long-acting Injectable Antipsychotics (LAIs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Long-acting Injectable Antipsychotics (LAIs) include Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Long-acting Injectable Antipsychotics (LAIs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Injectable Antipsychotics (LAIs).
The Long-acting Injectable Antipsychotics (LAIs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Long-acting Injectable Antipsychotics (LAIs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Injectable Antipsychotics (LAIs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Alkermes Pharma Ireland Limited
Essential Pharma
Janssen Pharmaceuticals
Indivior UK Limited
Qilu Pharmaceutical
Lvye Pharmaceutical
Segment by Type
First-generation
Second-generation
Segment by Application
Schizophrenia
Bipolar Disorder
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Long-acting Injectable Antipsychotics (LAIs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Long-acting Injectable Antipsychotics (LAIs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.
The global Long-acting Injectable Antipsychotics (LAIs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Long-acting Injectable Antipsychotics (LAIs) include Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Long-acting Injectable Antipsychotics (LAIs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Injectable Antipsychotics (LAIs).
The Long-acting Injectable Antipsychotics (LAIs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Long-acting Injectable Antipsychotics (LAIs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Injectable Antipsychotics (LAIs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Alkermes Pharma Ireland Limited
Essential Pharma
Janssen Pharmaceuticals
Indivior UK Limited
Qilu Pharmaceutical
Lvye Pharmaceutical
Segment by Type
First-generation
Second-generation
Segment by Application
Schizophrenia
Bipolar Disorder
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Long-acting Injectable Antipsychotics (LAIs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Long-acting Injectable Antipsychotics (LAIs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Long-acting Injectable Antipsychotics (LAIs) Market Overview
1.1 Product Definition
1.2 Long-acting Injectable Antipsychotics (LAIs) by Type
1.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Value Comparison by Type (2024-2030)
1.2.2 First-generation
1.2.3 Second-generation
1.3 Long-acting Injectable Antipsychotics (LAIs) by Application
1.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Application (2024-2030)
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Other
1.4 Global Long-acting Injectable Antipsychotics (LAIs) Market Size Estimates and Forecasts
1.4.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue 2019-2030
1.4.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales 2019-2030
1.4.3 Global Long-acting Injectable Antipsychotics (LAIs) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Long-acting Injectable Antipsychotics (LAIs) Market Competition by Manufacturers
2.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Long-acting Injectable Antipsychotics (LAIs) Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Long-acting Injectable Antipsychotics (LAIs), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Product Type & Application
2.7 Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Date of Enter into This Industry
2.8 Global Long-acting Injectable Antipsychotics (LAIs) Market Competitive Situation and Trends
2.8.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Long-acting Injectable Antipsychotics (LAIs) Players Market Share by Revenue
2.8.3 Global Long-acting Injectable Antipsychotics (LAIs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Injectable Antipsychotics (LAIs) Market Scenario by Region
3.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region: 2019-2030
3.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region: 2019-2024
3.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region: 2025-2030
3.3 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2019-2030
3.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2019-2024
3.3.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2025-2030
3.4 North America Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.4.1 North America Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2030)
3.4.3 North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.5.1 Europe Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2030)
3.5.3 Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2030)
3.6.3 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.7.1 Latin America Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2030)
3.7.3 Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2030)
4.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2019-2024)
4.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2025-2030)
4.1.3 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2030)
4.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2019-2030)
4.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2019-2024)
4.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2025-2030)
4.2.3 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2019-2030)
4.3 Global Long-acting Injectable Antipsychotics (LAIs) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2030)
5.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2019-2024)
5.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2025-2030)
5.1.3 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2030)
5.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2019-2030)
5.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2019-2024)
5.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2025-2030)
5.2.3 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2019-2030)
5.3 Global Long-acting Injectable Antipsychotics (LAIs) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Otsuka Pharmaceutical
6.1.1 Otsuka Pharmaceutical Company Information
6.1.2 Otsuka Pharmaceutical Description and Business Overview
6.1.3 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.1.5 Otsuka Pharmaceutical Recent Developments/Updates
6.2 CHEPLAPHARM Arzneimittel GmbH
6.2.1 CHEPLAPHARM Arzneimittel GmbH Company Information
6.2.2 CHEPLAPHARM Arzneimittel GmbH Description and Business Overview
6.2.3 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.2.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
6.3 Alkermes Pharma Ireland Limited
6.3.1 Alkermes Pharma Ireland Limited Company Information
6.3.2 Alkermes Pharma Ireland Limited Description and Business Overview
6.3.3 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.3.5 Alkermes Pharma Ireland Limited Recent Developments/Updates
6.4 Essential Pharma
6.4.1 Essential Pharma Company Information
6.4.2 Essential Pharma Description and Business Overview
6.4.3 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.4.5 Essential Pharma Recent Developments/Updates
6.5 Janssen Pharmaceuticals
6.5.1 Janssen Pharmaceuticals Company Information
6.5.2 Janssen Pharmaceuticals Description and Business Overview
6.5.3 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.5.5 Janssen Pharmaceuticals Recent Developments/Updates
6.6 Indivior UK Limited
6.6.1 Indivior UK Limited Company Information
6.6.2 Indivior UK Limited Description and Business Overview
6.6.3 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.6.5 Indivior UK Limited Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.7.1 Qilu Pharmaceutical Company Information
6.7.2 Qilu Pharmaceutical Description and Business Overview
6.7.3 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 Lvye Pharmaceutical
6.8.1 Lvye Pharmaceutical Company Information
6.8.2 Lvye Pharmaceutical Description and Business Overview
6.8.3 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.8.5 Lvye Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Injectable Antipsychotics (LAIs) Industry Chain Analysis
7.2 Long-acting Injectable Antipsychotics (LAIs) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Injectable Antipsychotics (LAIs) Production Mode & Process
7.4 Long-acting Injectable Antipsychotics (LAIs) Sales and Marketing
7.4.1 Long-acting Injectable Antipsychotics (LAIs) Sales Channels
7.4.2 Long-acting Injectable Antipsychotics (LAIs) Distributors
7.5 Long-acting Injectable Antipsychotics (LAIs) Customers
8 Long-acting Injectable Antipsychotics (LAIs) Market Dynamics
8.1 Long-acting Injectable Antipsychotics (LAIs) Industry Trends
8.2 Long-acting Injectable Antipsychotics (LAIs) Market Drivers
8.3 Long-acting Injectable Antipsychotics (LAIs) Market Challenges
8.4 Long-acting Injectable Antipsychotics (LAIs) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Long-acting Injectable Antipsychotics (LAIs) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Long-acting Injectable Antipsychotics (LAIs) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Long-acting Injectable Antipsychotics (LAIs) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Long-acting Injectable Antipsychotics (LAIs), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Product Type & Application
Table 12. Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Long-acting Injectable Antipsychotics (LAIs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Injectable Antipsychotics (LAIs) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2024) & (K Units)
Table 18. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2019-2024)
Table 19. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2025-2030) & (K Units)
Table 20. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2025-2030)
Table 21. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2019-2024)
Table 23. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2025-2030)
Table 25. North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units)
Table 27. North America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2025-2030) & (K Units)
Table 28. North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units)
Table 32. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2025-2030) & (K Units)
Table 33. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Type (2019-2024)
Table 51. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Type (2025-2030)
Table 52. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2019-2024)
Table 53. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2025-2030)
Table 54. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2019-2024)
Table 57. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2025-2030)
Table 58. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Type (2019-2024)
Table 59. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Type (2025-2030)
Table 60. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Application (2019-2024)
Table 61. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Application (2025-2030)
Table 62. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2019-2024)
Table 63. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2025-2030)
Table 64. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2019-2024)
Table 67. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2025-2030)
Table 68. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Application (2019-2024)
Table 69. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Application (2025-2030)
Table 70. Otsuka Pharmaceutical Company Information
Table 71. Otsuka Pharmaceutical Description and Business Overview
Table 72. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product
Table 74. Otsuka Pharmaceutical Recent Developments/Updates
Table 75. CHEPLAPHARM Arzneimittel GmbH Company Information
Table 76. CHEPLAPHARM Arzneimittel GmbH Description and Business Overview
Table 77. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product
Table 79. CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
Table 80. Alkermes Pharma Ireland Limited Company Information
Table 81. Alkermes Pharma Ireland Limited Description and Business Overview
Table 82. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product
Table 84. Alkermes Pharma Ireland Limited Recent Developments/Updates
Table 85. Essential Pharma Company Information
Table 86. Essential Pharma Description and Business Overview
Table 87. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product
Table 89. Essential Pharma Recent Developments/Updates
Table 90. Janssen Pharmaceuticals Company Information
Table 91. Janssen Pharmaceuticals Description and Business Overview
Table 92. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product
Table 94. Janssen Pharmaceuticals Recent Developments/Updates
Table 95. Indivior UK Limited Company Information
Table 96. Indivior UK Limited Description and Business Overview
Table 97. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product
Table 99. Indivior UK Limited Recent Developments/Updates
Table 100. Qilu Pharmaceutical Company Information
Table 101. Qilu Pharmaceutical Description and Business Overview
Table 102. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product
Table 104. Qilu Pharmaceutical Recent Developments/Updates
Table 105. Lvye Pharmaceutical Company Information
Table 106. Lvye Pharmaceutical Description and Business Overview
Table 107. Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product
Table 109. Lvye Pharmaceutical Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Long-acting Injectable Antipsychotics (LAIs) Distributors List
Table 113. Long-acting Injectable Antipsychotics (LAIs) Customers List
Table 114. Long-acting Injectable Antipsychotics (LAIs) Market Trends
Table 115. Long-acting Injectable Antipsychotics (LAIs) Market Drivers
Table 116. Long-acting Injectable Antipsychotics (LAIs) Market Challenges
Table 117. Long-acting Injectable Antipsychotics (LAIs) Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Long-acting Injectable Antipsychotics (LAIs)
Figure 2. Global Long-acting Injectable Antipsychotics (LAIs) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Long-acting Injectable Antipsychotics (LAIs) Market Share by Type: 2023 & 2030
Figure 4. First-generation Product Picture
Figure 5. Second-generation Product Picture
Figure 6. Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Application (2024-2030) & (US$ Million)
Figure 7. Global Long-acting Injectable Antipsychotics (LAIs) Market Share by Application: 2023 & 2030
Figure 8. Schizophrenia
Figure 9. Bipolar Disorder
Figure 10. Other
Figure 11. Global Long-acting Injectable Antipsychotics (LAIs) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Long-acting Injectable Antipsychotics (LAIs) Market Size (2019-2030) & (US$ Million)
Figure 13. Global Long-acting Injectable Antipsychotics (LAIs) Sales (2019-2030) & (K Units)
Figure 14. Global Long-acting Injectable Antipsychotics (LAIs) Average Price (US$/Unit) & (2019-2030)
Figure 15. Long-acting Injectable Antipsychotics (LAIs) Report Years Considered
Figure 16. Long-acting Injectable Antipsychotics (LAIs) Sales Share by Manufacturers in 2023
Figure 17. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Share by Manufacturers in 2023
Figure 18. Global 5 and 10 Largest Long-acting Injectable Antipsychotics (LAIs) Players: Market Share by Revenue in Long-acting Injectable Antipsychotics (LAIs) in 2023
Figure 19. Long-acting Injectable Antipsychotics (LAIs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 20. Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2030)
Figure 22. North America Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2030)
Figure 23. United States Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2030)
Figure 26. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2030)
Figure 27. Germany Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2019-2030)
Figure 34. China Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Latin America Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2030)
Figure 42. Mexico Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Brazil Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Argentina Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Colombia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2019-2030)
Figure 47. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2019-2030)
Figure 48. Turkey Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. UAE Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Global Sales Market Share of Long-acting Injectable Antipsychotics (LAIs) by Type (2019-2030)
Figure 52. Global Revenue Market Share of Long-acting Injectable Antipsychotics (LAIs) by Type (2019-2030)
Figure 53. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Type (2019-2030)
Figure 54. Global Sales Market Share of Long-acting Injectable Antipsychotics (LAIs) by Application (2019-2030)
Figure 55. Global Revenue Market Share of Long-acting Injectable Antipsychotics (LAIs) by Application (2019-2030)
Figure 56. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Application (2019-2030)
Figure 57. Long-acting Injectable Antipsychotics (LAIs) Value Chain
Figure 58. Long-acting Injectable Antipsychotics (LAIs) Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
